Oppenheimer & Co. Inc. Has $1.63 Million Stock Position in Hologic, Inc. (NASDAQ:HOLX)

Oppenheimer & Co. Inc. cut its holdings in shares of Hologic, Inc. (NASDAQ:HOLX) by 1.5% in the third quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 19,975 shares of the medical equipment provider’s stock after selling 300 shares during the quarter. Oppenheimer & Co. Inc.’s holdings in Hologic were worth $1,627,000 as of its most recent SEC filing.

Other hedge funds also recently modified their holdings of the company. Empowered Funds LLC bought a new stake in Hologic in the 1st quarter valued at $234,000. Mitsubishi UFJ Trust & Banking Corp lifted its stake in shares of Hologic by 0.4% in the first quarter. Mitsubishi UFJ Trust & Banking Corp now owns 292,378 shares of the medical equipment provider’s stock valued at $22,490,000 after buying an additional 1,136 shares during the period. Acadian Asset Management LLC grew its position in Hologic by 11,074.7% during the first quarter. Acadian Asset Management LLC now owns 179,019 shares of the medical equipment provider’s stock worth $13,947,000 after buying an additional 177,417 shares in the last quarter. Trustmark National Bank Trust Department bought a new position in Hologic during the first quarter valued at about $204,000. Finally, Seven Eight Capital LP raised its holdings in Hologic by 35.3% in the 1st quarter. Seven Eight Capital LP now owns 4,169 shares of the medical equipment provider’s stock valued at $325,000 after acquiring an additional 1,088 shares in the last quarter. 94.73% of the stock is owned by institutional investors.

Wall Street Analysts Forecast Growth

Several analysts have recently weighed in on HOLX shares. Mizuho decreased their price objective on Hologic from $90.00 to $87.00 and set an “outperform” rating on the stock in a report on Tuesday, November 5th. Stephens reissued an “overweight” rating and issued a $92.00 price target on shares of Hologic in a report on Tuesday, July 30th. Citigroup downgraded shares of Hologic from a “buy” rating to a “neutral” rating and reduced their price objective for the stock from $95.00 to $85.00 in a report on Tuesday, October 1st. Needham & Company LLC reissued a “buy” rating and issued a $90.00 target price on shares of Hologic in a research note on Tuesday, October 15th. Finally, Leerink Partners cut their price target on shares of Hologic from $95.00 to $90.00 and set an “outperform” rating for the company in a research note on Tuesday, October 8th. Four equities research analysts have rated the stock with a hold rating and nine have issued a buy rating to the stock. According to data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $89.91.

Hologic Stock Up 1.4 %

NASDAQ HOLX opened at $78.60 on Monday. The stock’s 50 day simple moving average is $80.71 and its 200 day simple moving average is $78.26. The company has a debt-to-equity ratio of 0.49, a current ratio of 3.69 and a quick ratio of 3.03. Hologic, Inc. has a one year low of $67.59 and a one year high of $84.67. The firm has a market cap of $18.26 billion, a PE ratio of 23.60, a price-to-earnings-growth ratio of 2.48 and a beta of 0.98.

Hologic (NASDAQ:HOLX) last announced its earnings results on Monday, November 4th. The medical equipment provider reported $1.01 earnings per share for the quarter, meeting analysts’ consensus estimates of $1.01. Hologic had a return on equity of 19.79% and a net margin of 19.59%. The company had revenue of $987.90 million during the quarter, compared to analyst estimates of $978.25 million. During the same period last year, the company posted $0.89 earnings per share. The firm’s quarterly revenue was up 4.5% compared to the same quarter last year. As a group, sell-side analysts forecast that Hologic, Inc. will post 4.27 earnings per share for the current fiscal year.

About Hologic

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.